INS and obesity disorder: The study demonstrated the ability of the JAK inhibitor to correct abnormalities in insulin signaling in the liver and skeletal muscle, shedding further light on the pilot role of JAK2 in the regulation of different metabolic processes implicated in the development of diabetes and obesity.